Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P McGarvey

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
The European Respiratory Journal|August 22, 2014
Expert opinion on the cough hypersensitivity syndrome in respiratory medicineAlyn H Morice, Eva Millqvist, Maria G Belvisi, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|June 19, 2012
Eosinophil peroxidase induces the expression and function of acid-sensing ion channel-3 in allergic rhinitis: in vitro evidence in cultured epithelial cellsS G Khoo, M Al-Alawi, M T Walsh, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 15, 2022
Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic coughPeter V Dicpinigaitis, Surinder S Birring, Michael Blaiss, et al.
Lung|July 27, 2022
Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined SubgroupsJaclyn A Smith, Surinder S Birring, Peter V Dicpinigaitis, et al.
Lancet (London, England)|March 6, 2022
Efficacy and safety of gefapixant, a P2X<sub>3</sub> receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trialsLorcan P McGarvey, Surinder S Birring, Alyn H Morice, et al.
Nucleic Acids Research|November 7, 2007
An emerging cyberinfrastructure for biodefense pathogen and pathogen-host dataC Zhang, O Crasta, S Cammer, et al.
BMJ Open Respiratory Research|June 14, 2022
Large scale clinical trials: lessons from the COVID-19 pandemicAlex R Horsley, Laurence Pearmain, Sean Knight, et al.
The Journal of Allergy and Clinical Immunology|November 12, 2013
Increased expression of bronchial epithelial transient receptor potential vanilloid 1 channels in patients with severe asthmaLorcan P McGarvey, Claire A Butler, Susan Stokesberry, et al.
Allergy|May 17, 2022
Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker-high and -low severe asthmaLatifa Khalfaoui, Fiona A Symon, Simon Couillard, et al.
ERJ Open Research|November 29, 2023
Consensus goals and standards for specialist cough clinics: the NEUROCOUGH international Delphi studyWoo-Jung Song, Lieven Dupont, Surinder S Birring, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
The European Respiratory Journal|August 22, 2014
Expert opinion on the cough hypersensitivity syndrome in respiratory medicineAlyn H Morice, Eva Millqvist, Maria G Belvisi, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|June 19, 2012
Eosinophil peroxidase induces the expression and function of acid-sensing ion channel-3 in allergic rhinitis: in vitro evidence in cultured epithelial cellsS G Khoo, M Al-Alawi, M T Walsh, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 15, 2022
Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic coughPeter V Dicpinigaitis, Surinder S Birring, Michael Blaiss, et al.
Lung|July 27, 2022
Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined SubgroupsJaclyn A Smith, Surinder S Birring, Peter V Dicpinigaitis, et al.
Lancet (London, England)|March 6, 2022
Efficacy and safety of gefapixant, a P2X<sub>3</sub> receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trialsLorcan P McGarvey, Surinder S Birring, Alyn H Morice, et al.
Nucleic Acids Research|November 7, 2007
An emerging cyberinfrastructure for biodefense pathogen and pathogen-host dataC Zhang, O Crasta, S Cammer, et al.
BMJ Open Respiratory Research|June 14, 2022
Large scale clinical trials: lessons from the COVID-19 pandemicAlex R Horsley, Laurence Pearmain, Sean Knight, et al.
The Journal of Allergy and Clinical Immunology|November 12, 2013
Increased expression of bronchial epithelial transient receptor potential vanilloid 1 channels in patients with severe asthmaLorcan P McGarvey, Claire A Butler, Susan Stokesberry, et al.
Allergy|May 17, 2022
Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker-high and -low severe asthmaLatifa Khalfaoui, Fiona A Symon, Simon Couillard, et al.
ERJ Open Research|November 29, 2023
Consensus goals and standards for specialist cough clinics: the NEUROCOUGH international Delphi studyWoo-Jung Song, Lieven Dupont, Surinder S Birring, et al.
Pageof 6